pharmaceutical investing Aequus Extends and Enhances Commercial Agreement to Promote Vistitan in Canada
pharmaceutical investing Aequus and Camargo Prepare for Meeting with FDA to Advance Anti-Nausea Patch
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
